For example, Merrimack Pharmaceuticals (USA) has administered 64Cu-labeled HER2-targeted PEGylated liposomal doxorubicin to screen metastatic breast cancer patients as part of their MM-302 clinical trial (64), followed by PET/CT imaging. The gene discussed is ERBB2; the disease is breast cancer.